Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed is the share price of £12.70 per share used for dividend re-investment.
Material Changes
There are no material changes to the company's financial position or operations reported in this filing. The document solely reports an increase in share interests for specific individuals following the re-investment of dividends paid on April 8, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investors to Verify
- The filing confirms dividend re-investment transactions for four individuals: Mr E J Gray, Mr S A Hussain, Mr D S Redfern, and Ms C Thomas.
- The transaction price was £12.70 per share.
- This report does not contain financial performance data; investors should refer to the company's Form 20-F or interim reports for financial metrics.